iatroX logo
brainstormaskiatroXquizcpdknowledge centrehow it worksaboutblog
Knowledge Centre / Bladder Cancer

Bladder Cancer

Investigation and management of bladder cancer.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 August 2025
UrologyOncology

Clinical Guidelines

Bladder Cancer: ESMO Clinical Practice Guidelines
National
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
National
EAU Guidelines on Non-muscle-invasive Bladder Cancer
National
NICE guideline [NG12]: Suspected cancer: recognition and referral
National
NICE guideline [NG2]: Bladder Cancer
National
NICE guideline [NG2]: Bladder cancer: diagnosis and management
National

Recent iatroX Q&As

  • What are the key symptoms and risk factors for bladder cancer that I should be aware of in my patients?Updated: 8/16/2025
  • How should I approach the investigation of a patient with hematuria to rule out bladder cancer?Updated: 8/16/2025
  • What are the current guidelines for referring a patient with suspected bladder cancer to a urologist?Updated: 8/16/2025
  • What are the recommended follow-up protocols for patients diagnosed with non-muscle invasive bladder cancer?Updated: 8/16/2025
  • How can I effectively manage the side effects of treatment in patients undergoing therapy for bladder cancer?Updated: 8/16/2025
ask iatroX
privacy terms faq
UKCA Mark

iatroX is a UKCA-marked, MHRA-registered medical device.

Download on the App StoreGet it on Google Play